Skip to content
10-Q

Quarterly Report

LB Pharmaceuticals Inc LBRX

0001193125-26-219607

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 28.68M sh
Shares Diluted Q1 2026 · Mar 31, 2026 28.24M sh
Shares Diluted Q1 2026 · Mar 31, 2025 358.78K sh
Capex Q1 2026 · Mar 31, 2026 $32K
Capex Q1 2026 · Mar 31, 2025 $21K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$23.29M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.13M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $320.68M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $250.17M
Stockholders Equity Q1 2026 · Mar 31, 2026 $378.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 $301.31M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$99.34M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$94.55M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.91M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.79M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.62M
Current Assets Q1 2026 · Mar 31, 2026 $389.07M
Current Assets Q1 2026 · Dec 31, 2025 $308.43M
Total Assets Q1 2026 · Mar 31, 2026 $393.48M
Total Assets Q1 2026 · Dec 31, 2025 $312.93M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.67
Eps Diluted Q1 2026 · Mar 31, 2025 −$14.79
Eps Basic Q1 2026 · Mar 31, 2026 −$0.67
Eps Basic Q1 2026 · Mar 31, 2025 −$14.79
Sga Expense Q1 2026 · Mar 31, 2026 $7.46M
Sga Expense Q1 2026 · Mar 31, 2025 $3.01M
Rd Expense Q1 2026 · Mar 31, 2026 $14.65M
Rd Expense Q1 2026 · Mar 31, 2025 $3.42M
Net Income Q1 2026 · Mar 31, 2026 −$19.05M
Net Income Q1 2026 · Mar 31, 2025 −$5.31M